Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free CDNA Stock Alerts

CareDx (CDNA) Financials

CareDx logo
$20.96 +0.26 (+1.26%)
Closing price 03:59 PM Eastern
Extended Trading
$20.57 -0.39 (-1.85%)
As of 06:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for CareDx

Annual Income Statements for CareDx

This table shows CareDx's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -14 -39 -55 -47 -22 -19 -31 -77 -190 53 -21
Consolidated Net Income / (Loss)		 -14 -40 -56 -47 -22 -19 -31 -77 -190 53 -21
Net Income / (Loss) Continuing Operations		 -14 -40 -56 -47 -22 -19 -31 -77 -190 53 -21
Total Pre-Tax Income 		-14 -41 -57 -48 -24 -20 -32 -76 -190 53 -21
Total Operating Income		 -12 -37 -20 -16 -25 -23 -30 -77 -203 41 -31
Total Gross Profit		 18 20 27 44 82 129 199 210 178 224 257
Total Revenue		 28 41 48 77 127 192 296 322 280 334 380
Operating Revenue		 28 41 48 77 127 192 296 322 280 334 380
Total Cost of Revenue		 10 21 21 33 45 63 97 112 102 110 123
Operating Cost of Revenue		 10 21 21 33 45 63 97 112 102 110 123
Total Operating Expenses		 30 57 47 59 106 152 229 287 382 183 287
Selling, General & Admin Expense		 12 21 20 23 37 49 75 100 119 125 108
Marketing Expense		 8.35 11 13 22 39 54 77 96 84 82 103
Research & Development Expense		 9.33 12 12 15 31 49 77 90 82 73 71
Other Special Charges / (Income)		 -0.13 -0.46 - - - - 0.00 0.00 96 -96 5.71
Total Other Income / (Expense), net		 -1.78 -4.03 -37 -33 0.59 2.78 -2.36 1.00 13 12 9.70
Interest & Investment Income		 -1.59 -1.86 -5.86 -3.70 0.99 0.27 0.16 3.76 12 12 9.17
Other Income / (Expense), net		 -0.19 -2.17 -31 -23 -0.40 2.51 -2.52 -2.77 1.35 0.33 0.52
Income Tax Expense		 0.00 -1.61 -1.71 -1.43 -1.98 -1.04 -1.43 0.38 0.14 0.31 0.27
Basic Earnings per Share		 ($1.16) ($2.39) ($2.38) ($1.31) ($0.52) ($0.40) ($0.59) ($1.44) ($3.54) $1.00 ($0.40)
Weighted Average Basic Shares Outstanding		 11.86M 16.50M 23.33M 35.64M 42.15M 46.48M 52.24M 53.32M 53.76M 52.77M 53.29M
Diluted Earnings per Share		 ($1.16) ($2.39) ($2.38) ($1.31) ($0.52) ($0.40) ($0.59) ($1.44) ($3.54) $0.93 ($0.40)
Weighted Average Diluted Shares Outstanding		 11.86M 16.50M 23.33M 35.64M 42.15M 46.48M 52.24M 53.32M 53.76M 56.62M 53.29M
Weighted Average Basic & Diluted Shares Outstanding		 11.80M 16.50M 23.30M 35.70M 42.88M 51.82M 53.03M 53.67M 51.78M 55.43M 51.22M

Quarterly Income Statements for CareDx

This table shows CareDx's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -23 -118 -20 -4.62 -11 78 -10 -8.57 1.68 -4.11 2.81
Consolidated Net Income / (Loss)		 -23 -118 -20 -4.62 -11 78 -10 -8.57 1.68 -4.11 2.81
Net Income / (Loss) Continuing Operations		 -23 -118 -20 -4.62 -11 78 -10 -8.57 1.68 -4.11 2.81
Total Pre-Tax Income 		-24 -118 -20 -4.60 -10 78 -10 -8.69 1.66 -3.76 2.78
Total Operating Income		 -29 -123 -23 -7.33 -14 75 -13 -11 -0.25 -6.04 1.20
Total Gross Profit		 43 40 46 64 55 58 56 58 69 73 84
Total Revenue		 67 66 72 92 83 87 85 87 100 108 118
Operating Revenue		 67 66 72 92 83 87 85 87 100 108 118
Total Cost of Revenue		 25 26 26 28 28 28 28 29 31 36 34
Operating Cost of Revenue		 25 26 26 28 28 28 28 29 31 36 34
Total Operating Expenses		 71 163 69 72 69 -16 70 69 70 79 83
Selling, General & Admin Expense		 34 27 30 31 32 41 23 28 28 29 30
Marketing Expense		 18 20 20 21 20 21 23 24 24 31 30
Research & Development Expense		 19 18 19 20 17 17 19 17 17 19 21
Other Special Charges / (Income)		 - - 0.00 0.00 0.00 - 5.36 0.35 0.00 - 0.60
Total Other Income / (Expense), net		 5.22 4.70 2.60 2.73 3.28 3.49 3.08 2.44 1.91 2.28 1.58
Interest & Investment Income		 3.17 3.16 2.89 2.83 3.00 3.05 2.78 2.36 2.01 2.01 1.91
Other Income / (Expense), net		 2.05 1.54 -0.29 -0.10 0.28 0.44 0.30 0.07 -0.11 0.26 -0.33
Income Tax Expense		 -0.08 0.17 -0.08 0.02 0.20 0.17 0.06 -0.12 -0.02 0.35 -0.03
Basic Earnings per Share		 ($0.43) ($2.21) ($0.38) ($0.09) ($0.20) $1.49 ($0.19) ($0.16) $0.03 ($0.08) $0.05
Weighted Average Basic Shares Outstanding		 54.18M 53.76M 51.69M 52.20M 52.90M 52.77M 55.26M 54.30M 52.51M 53.29M 51.15M
Diluted Earnings per Share		 ($0.43) ($2.21) ($0.38) ($0.09) ($0.20) $1.42 ($0.19) ($0.16) $0.03 ($0.08) $0.05
Weighted Average Diluted Shares Outstanding		 54.18M 53.76M 51.69M 52.20M 52.90M 56.62M 55.26M 54.30M 53.74M 53.29M 53.13M
Weighted Average Basic & Diluted Shares Outstanding		 54.10M 51.78M 52.08M 52.74M 53.63M 55.43M 55.68M 53.23M 51.43M 51.22M 51.66M

Annual Cash Flow Statements for CareDx

This table details how cash moves in and out of CareDx's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -6.54 -13 8.97 38 -25 96 214 -258 -7.66 32 -49
Net Cash From Operating Activities		 -9.75 -17 -14 -4.01 -2.77 33 -19 -25 -18 38 42
Net Cash From Continuing Operating Activities		 -9.75 -17 -14 -4.01 -2.77 33 -19 -25 -18 38 42
Net Income / (Loss) Continuing Operations		 -14 -40 -56 -47 -22 -19 -31 -77 -190 53 -21
Consolidated Net Income / (Loss)		 -14 -40 -56 -47 -22 -19 -31 -77 -190 53 -21
Depreciation Expense		 0.80 2.92 3.73 4.22 5.52 7.01 8.80 12 14 14 15
Amortization Expense		 0.12 4.03 3.87 2.47 1.62 2.54 4.22 4.80 0.51 6.18 6.67
Non-Cash Adjustments To Reconcile Net Income		 1.34 15 34 36 22 25 40 48 48 66 37
Changes in Operating Assets and Liabilities, net		 1.70 1.02 0.05 0.15 -10 18 -42 -13 109 -101 4.53
Net Cash From Investing Activities		 -1.20 -21 -6.11 -7.93 -23 -100 48 -229 40 -0.48 2.16
Net Cash From Continuing Investing Activities		 -1.20 -21 -6.11 -7.93 -23 -100 48 -229 40 -0.48 2.16
Purchase of Property, Plant & Equipment		 -1.20 -0.55 -0.19 -2.04 -2.20 -7.11 -14 -21 -8.34 -6.48 -5.91
Acquisitions		 - 0.00 -5.92 -5.89 -20 -3.25 -22 -3.71 -7.58 0.00 -0.68
Purchase of Investments		 - - - 0.00 0.00 -90 -5.50 -315 -202 -161 -146
Sale and/or Maturity of Investments		 - - - - 0.00 0.00 89 112 258 167 155
Net Cash From Financing Activities		 4.41 25 29 50 -0.13 163 186 -4.54 -30 -5.61 -93
Net Cash From Continuing Financing Activities		 4.41 25 29 50 -0.13 163 186 -4.54 -30 -5.61 -93
Repurchase of Common Equity		 - - - - - 0.00 0.00 -0.64 -28 -0.52 -88
Issuance of Common Equity		 0.20 8.23 18 53 0.76 160 191 2.23 1.50 1.40 2.27
Other Financing Activities, net		 0.05 0.02 1.25 12 -0.72 3.83 -5.29 -6.12 -3.56 -6.48 -7.90
Effect of Exchange Rate Changes		 0.00 - - 0.00 - 0.27 -0.30 0.02 -0.11 0.53 -0.09
Cash Income Taxes Paid		 - - - 0.00 0.00 0.08 0.01 0.39 0.74 0.32 0.28

Quarterly Cash Flow Statements for CareDx

This table details how cash moves in and out of CareDx's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -12 6.22 11 2.49 -0.38 19 -26 -21 23 -26 12
Net Cash From Operating Activities		 -10 -8.38 -15 19 13 22 -27 9.90 37 21 4.33
Net Cash From Continuing Operating Activities		 -10 -8.38 -15 19 13 22 -27 9.90 37 21 4.33
Net Income / (Loss) Continuing Operations		 -23 -118 -20 -1.39 -7.41 78 -10 -8.57 1.68 -4.11 2.81
Consolidated Net Income / (Loss)		 -23 -118 -20 -1.39 -7.41 78 -10 -8.57 1.68 -4.11 2.81
Depreciation Expense		 3.66 3.63 3.82 3.54 3.47 3.36 3.60 3.72 3.81 3.88 3.90
Amortization Expense		 0.05 -0.10 2.85 0.78 1.78 0.77 2.18 1.06 2.28 1.16 2.33
Non-Cash Adjustments To Reconcile Net Income		 11 8.50 17 13 14 26 8.92 9.42 11 8.09 9.94
Changes in Operating Assets and Liabilities, net		 -1.34 98 -19 2.85 0.99 -87 -31 4.26 19 12 -15
Net Cash From Investing Activities		 -1.50 41 28 -12 -14 -2.11 1.33 23 12 -35 11
Net Cash From Continuing Investing Activities		 -1.50 41 28 -12 -14 -2.11 1.33 23 12 -35 11
Purchase of Property, Plant & Equipment		 -1.62 -1.59 -1.49 -1.79 -1.69 -1.52 -1.63 -1.01 -1.31 -1.97 -3.82
Purchase of Investments		 -58 -9.03 -58 -35 -50 -18 -52 -15 -17 -62 -40
Sale and/or Maturity of Investments		 61 52 87 26 37 17 55 39 31 29 55
Net Cash From Financing Activities		 -0.03 -27 -1.28 -4.85 1.42 -0.90 -0.64 -54 -26 -12 -2.91
Net Cash From Continuing Financing Activities		 -0.03 -27 -1.28 -4.85 1.42 -0.90 -0.64 -54 -26 -12 -2.91
Issuance of Common Equity		 1.04 - 0.53 - 0.87 - 0.87 1.40 - - 0.99
Other Financing Activities, net		 -0.25 -0.91 -1.29 -4.85 0.56 -0.90 -1.52 -5.21 -0.92 -0.26 -3.90
Effect of Exchange Rate Changes		 -0.11 0.11 0.03 0.02 0.08 0.41 -0.08 -0.01 -0.01 0.01 0.01

Annual Balance Sheets for CareDx

This table presents CareDx's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 56 77 84 131 152 369 567 543 467 491 413
Total Current Assets		 34 27 27 81 72 273 433 388 314 352 257
Cash & Equivalents		 30 17 17 65 38 135 348 90 82 115 65
Short-Term Investments		 - - - - 0.00 90 0.00 203 153 146 112
Accounts Receivable		 2.37 2.77 2.99 9.76 24 35 60 66 51 65 43
Inventories, net		 0.77 5.46 5.53 4.94 6.01 10 17 19 19 20 27
Prepaid Expenses		 1.34 1.19 1.35 1.80 3.63 3.76 7.93 9.22 7.76 7.07 11
Plant, Property, & Equipment, net		 2.43 2.93 2.08 0.00 0.00 0.00 0.00 0.00 35 34 33
Total Noncurrent Assets		 19 47 55 50 80 95 133 155 118 106 123
Long-Term Investments		 - - - - - - - - - 0.00 24
Goodwill		 12 14 12 12 24 24 37 38 40 40 40
Intangible Assets		 6.65 33 33 33 46 44 50 43 46 38 32
Other Noncurrent Operating Assets		 0.20 0.02 - 4.13 10 27 46 74 31 27 26
Other Noncurrent Nonoperating Assets		 - 0.14 9.58 0.19 0.26 0.27 0.21 0.52 0.59 0.59 0.55
Total Liabilities & Shareholders' Equity		 56 77 84 131 152 369 567 543 467 491 413
Total Liabilities		 26 57 90 35 53 91 101 112 205 113 110
Total Current Liabilities		 10 41 43 20 35 69 77 76 78 89 90
Accounts Payable		 1.64 3.07 3.39 4.71 5.51 9.65 13 9.94 13 7.69 9.99
Accrued Expenses		 3.13 5.58 3.74 5.64 17 21 38 49 45 43 42
Current Employee Benefit Liabilities		 2.37 3.85 5.01 9.16 12 18 26 17 20 38 38
Total Noncurrent Liabilities		 16 16 47 15 18 22 23 36 127 23 20
Noncurrent Deferred & Payable Income Tax Liabilities		 0.00 6.06 4.93 2.97 1.97 1.30 0.42 0.00 0.14 0.16 0.18
Other Noncurrent Operating Liabilities		 0.98 6.92 22 12 16 20 23 36 127 23 20
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 29 20 -5.95 96 99 278 466 431 261 378 303
Total Preferred & Common Equity		 29 19 -6.13 96 99 278 466 431 261 378 303
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 29 19 -6.13 96 99 278 466 431 261 378 303
Common Stock		 203 236 264 412 438 632 854 899 947 1,013 1,044
Retained Earnings		 -173 -213 -268 -312 -334 -353 -383 -460 -678 -626 -735
Accumulated Other Comprehensive Income / (Loss)		 0.00 -3.66 -2.35 -4.28 -5.21 -2.10 -4.67 -7.50 -6.96 -8.57 -5.52

Quarterly Balance Sheets for CareDx

This table presents CareDx's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 545 528 515 501 452 467 477 490 444 432 411
Total Current Assets		 388 371 361 345 303 321 334 350 307 300 269
Cash & Equivalents		 83 75 88 76 93 96 95 89 68 91 78
Short-Term Investments		 208 211 195 192 123 133 145 142 118 103 109
Accounts Receivable		 70 59 52 52 60 66 67 71 67 48 45
Inventories, net		 18 18 19 18 20 19 19 23 28 28 26
Prepaid Expenses		 8.37 8.16 7.68 7.31 6.90 6.34 7.34 25 26 30 11
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 34 34 34 33 32 31 33
Total Noncurrent Assets		 156 157 154 156 115 112 109 107 105 101 109
Long-Term Investments		 - - - - - - - - - - 11
Goodwill		 38 40 40 40 40 40 40 40 40 40 40
Intangible Assets		 44 46 44 46 43 42 40 37 36 33 32
Other Noncurrent Operating Assets		 75 71 70 69 31 29 28 29 28 27 25
Other Noncurrent Nonoperating Assets		 0.20 0.52 0.58 0.58 0.58 0.59 0.59 0.55 0.55 0.55 0.55
Total Liabilities & Shareholders' Equity		 545 528 515 501 452 467 477 490 444 432 411
Total Liabilities		 108 108 110 107 196 202 204 110 117 121 98
Total Current Liabilities		 70 72 74 73 70 78 81 85 93 99 79
Accounts Payable		 11 13 9.88 8.97 9.98 5.87 6.24 8.07 9.86 12 9.07
Accrued Expenses		 45 47 50 47 46 47 45 43 44 44 50
Current Employee Benefit Liabilities		 14 12 14 17 15 25 30 14 19 23 21
Total Noncurrent Liabilities		 38 36 35 34 125 122 121 25 24 22 18
Noncurrent Deferred & Payable Income Tax Liabilities		 0.01 - 0.05 0.14 0.04 0.05 0.20 0.13 0.13 0.12 0.13
Other Noncurrent Operating Liabilities		 38 36 35 34 125 122 121 25 24 22 18
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 437 420 405 394 256 265 273 379 327 311 314
Total Preferred & Common Equity		 437 420 405 394 256 265 273 379 327 311 314
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 437 420 405 394 256 265 273 379 327 311 314
Common Stock		 887 912 924 937 960 969 985 1,023 1,029 1,036 1,052
Retained Earnings		 -441 -485 -510 -534 -695 -697 -704 -637 -695 -719 -733
Accumulated Other Comprehensive Income / (Loss)		 -8.81 -7.44 -8.45 -8.67 -8.11 -7.96 -7.18 -7.09 -6.11 -5.96 -6.27

Annual Metrics And Ratios for CareDx

This table displays calculated financial ratios and metrics derived from CareDx's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 3.07% 44.37% 18.93% 58.45% 65.95% 51.25% 54.22% 8.57% -12.89% 19.07% 13.79%
EBITDA Growth		 -665.72% -190.47% -33.17% 26.06% 44.50% 41.10% -83.58% -230.66% -194.21% 132.85% -113.94%
EBIT Growth		 -967.57% -225.92% -28.97% 23.97% 35.63% 19.70% -61.07% -148.07% -152.53% 120.34% -173.63%
NOPAT Growth		 -1,054.56% -212.87% 45.64% 23.24% -57.48% 8.17% -31.95% -159.81% -163.32% 128.47% -153.17%
Net Income Growth		 -1,855.06% -190.04% -39.75% 15.80% 53.04% 14.81% -63.85% -149.86% -148.37% 127.62% -140.64%
EPS Growth		 -1,260.00% -106.03% 0.42% 44.96% 60.31% 23.08% -47.50% -144.07% -145.83% 126.27% -143.01%
Operating Cash Flow Growth		 -191.10% -69.43% 13.41% 71.99% 30.90% 1,307.33% -157.71% -30.81% 27.14% 306.92% 10.47%
Free Cash Flow Firm Growth		 63.97% -398.86% 128.23% -485.91% -15.30% 82.92% -972.11% 13.02% 59.05% -69.02% 89.23%
Invested Capital Growth		 -5.65% 71.26% -93.80% 1,808.03% 94.48% -12.91% 122.33% 17.17% -81.56% 362.78% -13.67%
Revenue Q/Q Growth		 -4.43% 11.56% 3.52% 16.79% 10.73% 6.22% 12.16% 0.99% -5.66% 6.72% 6.09%
EBITDA Q/Q Growth		 -62.11% -86.67% -49.56% 47.39% -23.60% 32.43% -399.84% -4.37% -118.37% 145.42% -110.56%
EBIT Q/Q Growth		 -72.13% -72.26% -39.46% 43.15% -21.08% 18.71% -103.30% -3.84% -100.12% 126.49% -150.15%
NOPAT Q/Q Growth		 -69.46% -62.79% 41.80% 10.73% -14.62% 67.69% -208.83% -5.06% -103.67% 136.98% -136.18%
Net Income Q/Q Growth		 -53.13% -38.02% -40.15% 37.34% -4.85% 6.29% -70.10% -2.93% -110.22% 136.60% -130.31%
EPS Q/Q Growth		 -397.44% -6.22% -46.01% 48.43% -8.33% 13.04% -78.79% -2.13% -111.98% 134.44% -131.25%
Operating Cash Flow Q/Q Growth		 -50.08% 5.25% 5.99% 50.86% -987.50% 32.84% -18.52% 10.68% -551.59% 389.17% -1.24%
Free Cash Flow Firm Q/Q Growth		 0.00% 10.22% 364.04% -74.68% -16.53% 83.08% -144.01% 15.71% 39.32% -196.21% 76.68%
Invested Capital Q/Q Growth		 -1.97% -35.71% -92.03% -0.82% 7.37% -3.44% 7.84% -5.44% -79.80% 253.95% -13.06%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 63.50% 48.02% 55.78% 56.92% 64.23% 67.16% 67.14% 65.13% 63.61% 67.16% 67.55%
EBITDA Margin		 -39.82% -80.12% -89.71% -41.86% -14.00% -5.45% -6.49% -19.76% -66.75% 18.42% -2.26%
Operating Margin		 -42.40% -91.88% -42.00% -20.35% -19.31% -11.72% -10.03% -24.00% -72.55% 12.21% -8.10%
EBIT Margin		 -43.06% -97.22% -105.43% -50.59% -19.62% -10.42% -10.88% -24.86% -72.06% 12.31% -7.97%
Profit (Net Income) Margin		 -48.70% -97.85% -114.97% -61.10% -17.29% -9.74% -10.34% -23.81% -67.88% 15.74% -5.62%
Tax Burden Percent		 100.00% 96.12% 97.02% 97.03% 91.74% 94.75% 95.56% 100.50% 100.07% 99.41% 101.29%
Interest Burden Percent		 113.09% 104.71% 112.41% 124.48% 96.05% 98.65% 99.50% 95.30% 94.13% 128.63% 69.68%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.59% 0.00%
Return on Invested Capital (ROIC)		 -52.80% -125.45% -101.71% -66.59% -37.48% -27.85% -24.50% -42.49% -175.07% 56.87% -19.73%
ROIC Less NNEP Spread (ROIC-NNEP)		 -25.45% 233.45% -687.13% 58.80% -28.19% -25.62% -21.06% -35.47% -156.97% 52.04% -19.82%
Return on Net Nonoperating Assets (RNNOA)		 14.08% -35.98% -703.10% -37.40% 14.94% 17.92% 16.25% 25.40% 120.10% -40.44% 13.47%
Return on Equity (ROE)		 -38.72% -161.43% -804.81% -103.99% -22.54% -9.94% -8.25% -17.09% -54.98% 16.43% -6.27%
Cash Return on Invested Capital (CROIC)		 -46.98% -177.99% 74.94% -246.67% -101.64% -14.05% -100.40% -58.30% -37.36% -72.05% -5.06%
Operating Return on Assets (OROA)		 -20.76% -59.69% -63.57% -36.16% -17.66% -7.70% -6.90% -14.42% -40.01% 8.58% -6.69%
Return on Assets (ROA)		 -23.48% -60.07% -69.32% -43.67% -15.56% -7.19% -6.56% -13.81% -37.69% 10.97% -4.72%
Return on Common Equity (ROCE)		 -38.72% -160.51% -778.05% -103.78% -22.54% -9.94% -8.25% -17.09% -54.98% 16.43% -6.27%
Return on Equity Simple (ROE_SIMPLE)		 -46.47% -204.07% 905.77% -48.77% -22.19% -6.74% -6.58% -17.78% -72.81% 13.89% 0.00%
Net Operating Profit after Tax (NOPAT)		 -8.35 -26 -14 -11 -17 -16 -21 -54 -142 41 -22
NOPAT Margin		 -29.68% -64.32% -29.40% -14.24% -13.51% -8.21% -7.02% -16.80% -50.78% 12.14% -5.67%
Net Nonoperating Expense Percent (NNEP)		 -27.35% -358.89% 585.42% -125.39% -9.29% -2.24% -3.44% -7.02% -18.10% 4.84% 0.08%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -12.55% -54.47% 10.71% -7.11%
Cost of Revenue to Revenue		 36.50% 51.98% 44.22% 43.08% 35.77% 32.84% 32.86% 34.87% 36.39% 32.84% 32.45%
SG&A Expenses to Revenue		 43.52% 51.01% 41.58% 30.01% 28.76% 25.39% 25.29% 31.20% 42.05% 37.08% 28.32%
R&D to Revenue		 33.16% 30.48% 25.64% 18.96% 24.17% 25.46% 25.82% 28.09% 29.20% 21.69% 18.81%
Operating Expenses to Revenue		 105.89% 139.90% 97.77% 77.26% 83.53% 78.88% 77.17% 89.13% 136.16% 54.94% 75.66%
Earnings before Interest and Taxes (EBIT)		 -12 -40 -51 -39 -25 -20 -32 -80 -202 41 -30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -11 -33 -43 -32 -18 -10 -19 -64 -187 61 -8.57
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.58 2.95 0.00 10.20 9.25 12.85 5.15 1.42 2.48 3.03 3.20
Price to Tangible Book Value (P/TBV)		 7.03 0.00 0.00 19.30 30.92 17.04 6.34 1.74 3.70 3.83 4.20
Price to Revenue (P/Rev)		 2.71 1.41 4.34 12.77 7.20 18.57 8.10 1.90 2.32 3.44 2.55
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 21.85 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.58% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 4.04 2.45 139.32 29.35 14.49 63.45 17.52 2.31 16.34 7.57 7.59
Enterprise Value to Revenue (EV/Rev)		 2.20 1.59 4.70 11.93 6.90 17.40 6.93 0.99 1.48 2.66 2.02
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 14.44 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 21.60 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 21.90 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 100.03 0.00 0.00 0.00 23.33 18.26
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 21.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.53 1.21 -5.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.44 0.06 -3.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.55 -0.15 1.02 -0.64 -0.53 -0.70 -0.77 -0.72 -0.77 -0.78 -0.68
Leverage Ratio		 1.65 2.69 11.61 2.38 1.45 1.38 1.26 1.24 1.46 1.50 1.33
Compound Leverage Factor		 1.87 2.81 13.05 2.96 1.39 1.36 1.25 1.18 1.37 1.93 0.92
Debt to Total Capital		 34.82% 54.79% 121.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 6.33% 52.27% 55.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 28.48% 2.51% 65.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.64% 0.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 65.18% 44.58% -21.83% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -1.41 -0.74 -0.79 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 1.26 -0.21 -0.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -1.15 -0.03 -0.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -1.89 -0.92 -2.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 1.69 -0.26 -1.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -1.54 -0.04 -1.29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -2.30 -4.66 -4.75 13.71 7.92 23.24 14.44 2.88 -0.36 5.93 3.95
Noncontrolling Interest Sharing Ratio		 0.00% 0.57% 3.32% 0.20% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.38 0.65 0.62 4.16 2.07 3.95 5.61 5.11 4.02 3.94 2.86
Quick Ratio		 3.18 0.49 0.46 3.81 1.79 3.75 5.28 4.73 3.67 3.64 2.45
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -7.43 -37 10 -40 -47 -7.95 -85 -74 -30 -51 -5.53
Operating Cash Flow to CapEx		 -813.34% -3,009.65% -7,691.94% -196.90% -125.81% 470.20% -142.30% -118.86% -220.37% 586.80% 710.84%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 22.80 -6.99 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 -31.17 -0.69 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -31.58 -1.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.48 0.61 0.60 0.71 0.90 0.74 0.63 0.58 0.56 0.70 0.84
Accounts Receivable Turnover		 11.14 15.83 16.78 12.01 7.52 6.55 6.28 5.10 4.78 5.77 7.08
Inventory Turnover		 14.15 6.78 3.89 6.30 8.30 7.88 7.16 6.16 5.27 5.63 5.33
Fixed Asset Turnover		 12.81 15.17 19.31 0.00 0.00 0.00 0.00 0.00 0.00 9.70 11.42
Accounts Payable Turnover		 7.41 8.97 6.62 8.14 8.90 8.33 8.47 9.64 8.94 10.67 13.95
Days Sales Outstanding (DSO)		 32.77 23.06 21.75 30.39 48.57 55.72 58.12 71.50 76.41 63.24 51.53
Days Inventory Outstanding (DIO)		 25.79 53.80 93.85 57.94 43.99 46.34 50.97 59.23 69.25 64.88 68.43
Days Payable Outstanding (DPO)		 49.24 40.69 55.13 44.82 41.02 43.83 43.08 37.86 40.82 34.22 26.17
Cash Conversion Cycle (CCC)		 9.32 36.18 60.47 43.50 51.54 58.23 66.00 92.87 104.84 93.90 93.78
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 15 26 1.63 31 61 53 117 137 25 117 101
Invested Capital Turnover		 1.78 1.95 3.46 4.68 2.77 3.39 3.49 2.53 3.45 4.68 3.48
Increase / (Decrease) in Invested Capital		 -0.92 11 -25 29 29 -7.82 64 20 -112 92 -16
Enterprise Value (EV)		 62 64 227 913 877 3,344 2,053 318 414 888 768
Market Capitalization		 76 57 210 978 915 3,569 2,401 611 649 1,148 969
Book Value per Share		 $2.48 $0.92 ($0.21) $2.47 $2.33 $5.64 $8.82 $8.05 $4.83 $7.06 $5.89
Tangible Book Value per Share		 $0.91 ($1.29) ($1.79) $1.30 $0.70 $4.25 $7.17 $6.54 $3.24 $5.59 $4.49
Total Capital		 45 44 28 96 99 278 466 431 261 378 303
Total Debt		 16 24 34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 13 1.10 18 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -14 6.69 17 -65 -38 -225 -348 -293 -235 -261 -201
Capital Expenditures (CapEx)		 1.20 0.55 0.19 2.04 2.20 7.11 14 21 8.34 6.48 5.91
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.81 -8.57 -17 -3.01 -1.13 -21 7.57 19 0.22 1.81 -9.93
Debt-free Net Working Capital (DFNWC)		 27 8.69 -0.42 62 37 204 356 312 236 262 167
Net Working Capital (NWC)		 24 -14 -16 62 37 204 356 312 236 262 167
Net Nonoperating Expense (NNE)		 5.35 14 41 36 4.80 2.94 9.85 23 48 -12 -0.19
Net Nonoperating Obligations (NNO)		 -14 6.54 7.59 -65 -38 -225 -349 -294 -236 -261 -202
Total Depreciation and Amortization (D&A)		 0.91 6.95 7.60 6.68 7.14 9.54 13 16 15 20 22
Debt-free, Cash-free Net Working Capital to Revenue		 -9.99% -21.09% -35.83% -3.93% -0.89% -10.83% 2.56% 5.84% 0.08% 0.54% -2.61%
Debt-free Net Working Capital to Revenue		 96.21% 21.38% -0.87% 80.46% 29.19% 106.08% 120.13% 96.92% 84.06% 78.63% 44.04%
Net Working Capital to Revenue		 86.02% -34.85% -33.40% 80.46% 29.19% 106.08% 120.13% 96.92% 84.06% 78.63% 44.04%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.16) ($2.39) ($2.38) ($1.31) ($0.52) ($0.40) ($0.59) ($1.44) ($3.54) $1.00 ($0.40)
Adjusted Weighted Average Basic Shares Outstanding		 11.86M 16.50M 23.33M 35.64M 42.15M 46.48M 52.24M 53.32M 53.76M 52.77M 53.29M
Adjusted Diluted Earnings per Share		 ($1.16) ($2.39) ($2.38) ($1.31) ($0.52) ($0.40) ($0.59) ($1.44) ($3.54) $0.93 ($0.40)
Adjusted Weighted Average Diluted Shares Outstanding		 11.86M 16.50M 23.33M 35.64M 42.15M 46.48M 52.24M 53.32M 53.76M 56.62M 53.29M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 11.97M 16.50M 29.07M 41.73M 42.88M 51.82M 53.03M 53.67M 51.78M 55.43M 51.22M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.44 -17 -13 -11 -17 -16 -21 -54 -73 -53 -18
Normalized NOPAT Margin		 -29.99% -42.67% -26.56% -14.24% -13.51% -8.21% -7.02% -16.80% -26.16% -16.01% -4.62%
Pre Tax Income Margin		 -48.70% -101.80% -118.51% -62.97% -18.85% -10.28% -10.83% -23.69% -67.83% 15.84% -5.55%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -111.00 -6.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 -30.95 -1.89 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 -111.40 -7.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -31.35 -2.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.84% -14.47% 0.99% -411.01%

Quarterly Metrics And Ratios for CareDx

This table displays calculated financial ratios and metrics derived from CareDx's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 51,216,344.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 51,216,344.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 0.05
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -15.33% -20.41% -6.75% 31.26% 23.35% 32.04% 17.54% -6.06% 20.72% 25.19% 38.99%
EBITDA Growth		 -75.50% -628.78% 41.91% 100.53% 78.44% 167.42% 54.88% -102.29% 170.07% -100.83% 197.21%
EBIT Growth		 -49.39% -504.67% 25.35% 84.95% 61.82% 162.04% 42.78% -48.77% 97.37% -106.81% 106.64%
NOPAT Growth		 -66.00% -541.38% 20.50% 85.17% 63.55% 186.82% 40.73% -51.78% 97.42% -105.02% 112.94%
Net Income Growth		 -38.64% -544.32% 29.85% 94.41% 68.46% 166.06% 47.94% -85.33% 115.75% -104.68% 127.13%
EPS Growth		 -34.38% -550.00% 27.27% 93.48% 67.44% 164.25% 50.00% -77.78% 115.00% -105.00% 126.32%
Operating Cash Flow Growth		 -43.79% -216.65% -2,381.97% 3,897.39% 223.02% 361.17% -73.62% -47.78% 198.34% -2.40% 116.30%
Free Cash Flow Firm Growth		 99.36% 178.00% 732.63% 2,073.64% 27,394.31% -166.36% -251.47% -239.40% -201.04% 253.99% 129.43%
Invested Capital Growth		 -13.66% -81.56% -69.25% -69.80% -73.59% 362.78% 260.08% 281.66% 251.46% -13.67% -22.30%
Revenue Q/Q Growth		 -4.42% -2.42% 9.88% 28.07% -10.18% 4.46% -2.19% 2.35% 15.43% 8.33% 8.59%
EBITDA Q/Q Growth		 4.97% -410.57% 88.98% 101.00% -3,948.06% 1,696.70% -109.21% 14.12% 191.55% -112.82% 1,064.40%
EBIT Q/Q Growth		 4.14% -352.91% 83.79% 78.61% -143.19% 835.90% -117.41% 15.52% 96.81% -1,536.26% 115.03%
NOPAT Q/Q Growth		 -4.20% -326.06% 84.23% 78.81% -156.03% 1,114.77% -112.56% 16.85% 96.81% -1,603.31% 128.66%
Net Income Q/Q Growth		 5.88% -402.86% 85.89% 91.63% -431.42% 1,153.05% -113.27% 17.24% 119.55% -345.25% 168.38%
EPS Q/Q Growth		 6.52% -413.95% 85.52% 90.63% -366.67% 1,114.29% -113.38% 15.79% 118.75% -366.67% 162.50%
Operating Cash Flow Q/Q Growth		 -1,939.88% 17.66% -82.70% 223.75% -33.92% 74.80% -221.45% 137.22% 277.54% -42.82% -79.72%
Free Cash Flow Firm Q/Q Growth		 92.54% 8,500.39% 202.13% 4.18% 3.23% -120.42% -569.89% 4.01% 25.12% 114.12% 189.96%
Invested Capital Q/Q Growth		 2.80% -79.80% 62.17% -10.32% -10.10% 253.95% 26.18% -4.95% -17.21% -13.06% 13.57%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 63.49% 60.94% 64.01% 69.71% 66.73% 67.45% 66.45% 66.94% 69.36% 67.24% 71.43%
EBITDA Margin		 -34.27% -179.29% -17.98% 0.14% -5.99% 91.55% -8.62% -7.23% 5.74% -0.68% 6.03%
Operating Margin		 -42.84% -187.03% -26.84% -4.44% -12.66% 86.27% -15.79% -12.83% -0.25% -5.57% 1.02%
EBIT Margin		 -39.79% -184.68% -27.24% -4.55% -12.32% 86.77% -15.44% -12.75% -0.35% -5.33% 0.74%
Profit (Net Income) Margin		 -34.95% -180.11% -23.12% -1.51% -8.94% 90.10% -12.23% -9.88% 1.67% -3.79% 2.39%
Tax Burden Percent		 99.66% 100.14% 99.50% 101.60% 102.77% 99.78% 100.56% 98.65% 100.90% 109.17% 101.15%
Interest Burden Percent		 88.14% 97.39% 85.30% 32.68% 70.60% 104.06% 78.71% 78.60% -470.26% 65.15% 319.93%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.22% 0.00% 0.00% -0.90% 0.00% -1.15%
Return on Invested Capital (ROIC)		 -65.86% -451.35% -59.19% -11.63% -34.98% 403.21% -40.54% -34.51% -1.19% -13.57% 3.23%
ROIC Less NNEP Spread (ROIC-NNEP)		 -64.67% -439.16% -57.95% -12.21% -34.95% 401.81% -40.09% -34.13% -2.07% -13.62% 2.49%
Return on Net Nonoperating Assets (RNNOA)		 43.61% 335.99% 42.98% 9.32% 26.65% -312.30% 28.17% 23.91% 1.54% 9.26% -1.55%
Return on Equity (ROE)		 -22.25% -115.35% -16.21% -2.32% -8.32% 90.91% -12.36% -10.61% 0.35% -4.31% 1.69%
Cash Return on Invested Capital (CROIC)		 -37.00% -37.36% -53.11% -46.94% -21.88% -72.05% -60.56% -65.19% -31.72% -5.06% 16.46%
Operating Return on Assets (OROA)		 -22.61% -102.53% -15.28% -2.75% -7.88% 60.48% -11.36% -9.54% -0.28% -4.48% 0.68%
Return on Assets (ROA)		 -19.86% -100.00% -12.97% -0.91% -5.72% 62.80% -8.99% -7.40% 1.32% -3.18% 2.19%
Return on Common Equity (ROCE)		 -22.25% -115.35% -16.21% -2.32% -8.32% 90.91% -12.36% -10.61% 0.35% -4.31% 1.69%
Return on Equity Simple (ROE_SIMPLE)		 -22.97% 0.00% -71.50% -60.32% -52.54% 0.00% 16.37% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -20 -86 -14 -2.87 -7.34 75 -9.36 -7.78 -0.25 -4.23 1.21
NOPAT Margin		 -29.99% -130.92% -18.79% -3.11% -8.86% 86.08% -11.05% -8.98% -0.25% -3.90% 1.03%
Net Nonoperating Expense Percent (NNEP)		 -1.19% -12.18% -1.25% 0.58% -0.03% 1.40% -0.44% -0.38% 0.88% 0.05% 0.74%
Return On Investment Capital (ROIC_SIMPLE)		 - -32.85% - - - 19.69% -2.47% -2.38% -0.08% -1.39% 0.39%
Cost of Revenue to Revenue		 36.51% 39.06% 35.99% 30.29% 33.27% 32.55% 33.55% 33.06% 30.64% 32.76% 28.57%
SG&A Expenses to Revenue		 50.55% 40.48% 37.35% 30.00% 34.40% 46.99% 26.89% 31.94% 28.41% 26.46% 25.90%
R&D to Revenue		 28.28% 27.87% 25.97% 21.33% 21.10% 19.09% 21.87% 19.42% 16.76% 17.81% 18.20%
Operating Expenses to Revenue		 106.33% 247.96% 90.84% 74.16% 79.39% -18.82% 82.24% 79.77% 69.61% 72.81% 70.41%
Earnings before Interest and Taxes (EBIT)		 -27 -121 -20 -4.20 -10 75 -13 -11 -0.35 -5.78 0.87
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -23 -118 -13 0.13 -4.96 79 -7.30 -6.27 5.74 -0.74 7.10
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.96 2.48 2.14 3.06 6.03 3.03 2.59 3.32 2.49 3.20 2.84
Price to Tangible Book Value (P/TBV)		 1.23 3.70 3.18 4.43 8.55 3.83 3.26 4.33 3.26 4.20 3.69
Price to Revenue (P/Rev)		 1.28 2.32 1.99 2.72 5.27 3.44 2.84 3.19 2.16 2.55 2.15
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 21.85 15.85 18.71 10.99 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 4.58% 6.31% 5.34% 9.10% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.89 16.34 8.09 15.75 42.46 7.57 5.09 6.42 4.98 7.59 6.01
Enterprise Value to Revenue (EV/Rev)		 0.37 1.48 1.21 1.95 4.50 2.66 2.17 2.65 1.62 2.02 1.67
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 14.44 10.70 13.42 7.15 0.00 118.49
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 21.60 14.80 19.08 9.61 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 21.90 15.18 19.64 9.73 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 180.76 23.33 28.12 50.88 13.62 18.26 9.47
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 31.95
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.67 -0.77 -0.74 -0.76 -0.76 -0.78 -0.70 -0.70 -0.74 -0.68 -0.62
Leverage Ratio		 1.26 1.46 1.45 1.47 1.47 1.50 1.48 1.54 1.56 1.33 1.30
Compound Leverage Factor		 1.11 1.42 1.24 0.48 1.03 1.56 1.17 1.21 -7.32 0.86 4.16
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 1.70 0.21 0.61 1.54 4.00 6.16 4.80 4.66 2.89 4.15 4.54
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.75 4.02 4.32 4.09 4.10 3.94 4.11 3.30 3.03 2.86 3.40
Quick Ratio		 4.40 3.67 3.93 3.77 3.78 3.64 3.55 2.72 2.44 2.45 2.93
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.31 26 79 82 85 -17 -116 -112 -84 12 34
Operating Cash Flow to CapEx		 -629.50% -525.78% -1,029.72% 1,058.60% 743.15% 1,438.17% -1,630.92% 982.62% 2,862.68% 1,083.87% 113.46%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.57 0.56 0.56 0.61 0.64 0.70 0.74 0.75 0.79 0.84 0.92
Accounts Receivable Turnover		 4.87 4.78 4.61 5.04 5.29 5.77 5.26 5.11 6.25 7.08 7.11
Inventory Turnover		 5.87 5.27 5.35 5.46 5.75 5.63 5.21 4.78 4.87 5.33 5.21
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 9.70 10.32 10.31 11.04 11.42 12.53
Accounts Payable Turnover		 10.81 8.94 8.93 13.21 14.08 10.67 12.42 14.33 12.99 13.95 14.99
Days Sales Outstanding (DSO)		 75.00 76.41 79.25 72.36 69.04 63.24 69.35 71.50 58.36 51.53 51.31
Days Inventory Outstanding (DIO)		 62.16 69.25 68.28 66.80 63.48 64.88 70.09 76.30 74.97 68.43 70.09
Days Payable Outstanding (DPO)		 33.78 40.82 40.87 27.64 25.93 34.22 29.38 25.47 28.10 26.17 24.35
Cash Conversion Cycle (CCC)		 103.39 104.84 106.65 111.51 106.59 93.90 110.06 122.33 105.23 93.78 97.05
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 125 25 41 37 33 117 148 141 116 101 115
Invested Capital Turnover		 2.20 3.45 3.15 3.74 3.95 4.68 3.67 3.84 4.79 3.48 3.14
Increase / (Decrease) in Invested Capital		 -20 -112 -92 -85 -92 92 107 104 83 -16 -33
Enterprise Value (EV)		 111 414 332 580 1,406 888 753 902 580 768 691
Market Capitalization		 379 649 548 809 1,647 1,148 984 1,088 774 969 889
Book Value per Share		 $7.28 $4.83 $4.95 $5.08 $5.18 $7.06 $6.84 $5.88 $5.85 $5.89 $6.12
Tangible Book Value per Share		 $5.68 $3.24 $3.33 $3.50 $3.65 $5.59 $5.44 $4.51 $4.46 $4.49 $4.71
Total Capital		 394 261 256 265 273 378 379 327 311 303 314
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -268 -235 -216 -229 -241 -261 -231 -186 -194 -201 -198
Capital Expenditures (CapEx)		 1.62 1.59 1.49 1.79 1.69 1.52 1.63 1.01 1.31 1.97 3.82
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 4.31 0.22 17 13 12 1.81 34 28 7.02 -9.93 3.07
Debt-free Net Working Capital (DFNWC)		 272 236 233 242 253 262 265 214 201 167 190
Net Working Capital (NWC)		 272 236 233 242 253 262 265 214 201 167 190
Net Nonoperating Expense (NNE)		 3.34 32 3.12 -1.47 0.06 -3.48 0.99 0.78 -1.92 -0.12 -1.60
Net Nonoperating Obligations (NNO)		 -269 -236 -215 -228 -240 -261 -231 -187 -195 -202 -199
Total Depreciation and Amortization (D&A)		 3.71 3.53 6.67 4.33 5.25 4.13 5.78 4.78 6.09 5.04 6.23
Debt-free, Cash-free Net Working Capital to Revenue		 1.45% 0.08% 6.17% 4.51% 3.77% 0.54% 9.83% 8.17% 1.96% -2.61% 0.74%
Debt-free Net Working Capital to Revenue		 91.71% 84.06% 84.65% 81.55% 80.78% 78.63% 76.48% 62.82% 56.21% 44.04% 46.08%
Net Working Capital to Revenue		 91.71% 84.06% 84.65% 81.55% 80.78% 78.63% 76.48% 62.82% 56.21% 44.04% 46.08%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.43) ($2.21) ($0.32) ($0.03) ($0.14) $1.49 ($0.19) ($0.16) $0.03 ($0.08) $0.05
Adjusted Weighted Average Basic Shares Outstanding		 54.18M 53.76M 51.69M 52.20M 52.90M 52.77M 55.26M 54.30M 52.51M 53.29M 51.15M
Adjusted Diluted Earnings per Share		 ($0.43) ($2.21) ($0.32) ($0.03) ($0.14) $1.42 ($0.19) ($0.16) $0.03 ($0.08) $0.05
Adjusted Weighted Average Diluted Shares Outstanding		 54.18M 53.76M 51.69M 52.20M 52.90M 56.62M 55.26M 54.30M 53.74M 53.29M 53.13M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 54.10M 51.78M 52.08M 52.74M 53.63M 55.43M 55.68M 53.23M 51.43M 51.22M 51.66M
Normalized Net Operating Profit after Tax (NOPAT)		 -20 -86 -14 -2.82 -7.34 75 -5.61 -7.54 -0.17 -4.23 1.26
Normalized NOPAT Margin		 -29.99% -130.92% -18.79% -3.06% -8.86% 86.08% -6.62% -8.70% -0.17% -3.90% 1.07%
Pre Tax Income Margin		 -35.07% -179.86% -23.24% -1.49% -8.70% 90.30% -12.16% -10.02% 1.66% -3.47% 2.36%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -2.44% -14.47% -14.94% -17.11% -18.45% 0.99% 0.00% 86.00% 107.26% -411.01% 0.00%

Financials Breakdown Chart

Key Financial Trends

CareDx, Inc. (CDNA) has published quarterly results for 2025 and the prior years across income statements, cash flow statements, and balance sheets. Below is a concise, investor-focused summary of notable trends from the last four years, with a focus on the four most recent quarters.

  • Revenue growth with expanding scale: Revenue has trended higher from 2023 through 2025, with 2023 Q4 at about $65.6M, 2024 Q4 near $86.6M, and 2025 Q4 at $108.4M. This points to a meaningful growth trajectory in CareDx’s top line.
  • Gross margin stable in the mid-to-high 60s: Across recent quarters, gross margin has remained around 66%–69%. For example, 2025 Q4 shows Total Revenue of $108.386M and Total Gross Profit of $72.874M (about 67.3% gross margin), echoing the margin consistency seen in 2024–2025 periods.
  • Operating cash flow turning positive in 2025: Cash flow from continuing operating activities improved from negative in Q1 2025 to positive in subsequent quarters (Q2 2025: +$9.9M; Q3 2025: +$37.4M; Q4 2025: +$21.4M). This signals better cash generation as the year progressed.
  • Quarterly profitability seen in Q3 2025: Q3 2025 shows a positive near-term earnings signal, with Basic and Diluted Earnings per Share of about $0.03 and a net income metric implying a small positive quarterly result. This indicates a potential path toward quarterly profitability, even if not yet sustained every quarter.
  • Liquidity on solid footing: As of 2025 Q3, cash and short-term investments totaled roughly $194M (cash around $91M and short-term investments around $103M), contributing to a healthy liquidity position relative to current liabilities.
  • Conservative leverage profile: The latest quarters show total liabilities well below total equity (e.g., Q3 2025: Liabilities ~$121M vs. Equity ~$311M), suggesting a modest leverage posture and substantial equity cushion.
  • Capital return through share repurchases: CareDx has engaged in share repurchases in 2025 (e.g., notable programs in Q3 and Q4 2025), which can be a positive signal of capital allocation and confidence from management about the business trajectory.
  • Meaningful investing activity and portfolio moves: Quarterly cash flow shows ongoing investments in marketable securities (e.g., sizable purchases of investments in several quarters, offset by sales/maturities). This indicates active balance sheet management and portfolio positioning.
  • Net income remains largely negative outside a quarterly uptick: Despite the quarterly improvement, CareDx’s net income attributable to common shareholders has been negative in most periods (e.g., Q4 2025 net income -$4.11M; Q1 2025 and several other quarters also posted losses). Operating income also remained negative in multiple quarters, underscoring ongoing profitability risk despite revenue growth and cash-flow improvements.
05/06/26 09:29 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About CareDx's Financials

When does CareDx's fiscal year end?

According to the most recent income statement we have on file, CareDx's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has CareDx's net income changed over the last 10 years?

CareDx's net income appears to be on an upward trend, with a most recent value of -$21.35 million in 2025, rising from -$13.71 million in 2015. The previous period was $52.55 million in 2024. View CareDx's forecast to see where analysts expect CareDx to go next.

What is CareDx's operating income?
CareDx's total operating income in 2025 was -$30.78 million, based on the following breakdown:
  • Total Gross Profit: $256.57 million
  • Total Operating Expenses: $287.35 million
How has CareDx's revenue changed over the last 10 years?

Over the last 10 years, CareDx's total revenue changed from $28.14 million in 2015 to $379.81 million in 2025, a change of 1,249.5%.

How much debt does CareDx have?

CareDx's total liabilities were at $110.13 million at the end of 2025, a 2.2% decrease from 2024, and a 321.2% increase since 2015.

How much cash does CareDx have?

In the past 10 years, CareDx's cash and equivalents has ranged from $16.90 million in 2017 to $348.49 million in 2021, and is currently $65.43 million as of their latest financial filing in 2025.

How has CareDx's book value per share changed over the last 10 years?

Over the last 10 years, CareDx's book value per share changed from 2.48 in 2015 to 5.89 in 2025, a change of 137.8%.


Related Companies

Financial statements for NASDAQ:CDNA last updated on 5/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely, LLC | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Military ‘Dark Energy’ to Power AI
When it was put inside U.S. tanks, they moved almost silently and produced no smoke. Now, Elon Musk is using t...
Altimetry | Sponsoredtc pixel
Revealed: The World’s First Trillion-Dollar Robot
Jensen Huang stood in Las Vegas and laid out Nvidia's vision for building the world's first trillion-dollar ro...
Weiss Ratings | Sponsoredtc pixel
Is the SpaceX IPO “Rigged?”
The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...
The Oxford Club | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel